AbbVie Inc. has disclosed a transaction involving stock equivalent units acquired by director Edward J. Rapp. This event is significant as it highlights the company's ongoing strategies for compensating its directors and aligning their interests with that of shareholders.
Background
AbbVie Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a prominent player in the life sciences sector. The company is listed on the New York Stock Exchange under the ticker ABBV. Recent filings include a mix of reports, with the latest being a Form 4 filed on October 2, 2026.
What the Filing Says
The filing indicates that Rapp acquired 129 stock equivalent units at a transaction price of $261.59 per unit on September 30, 2026. Following this transaction, he owns a total of 29,568 shares, which includes stock equivalent units.
Impact
This acquisition may affect other directors and executives within AbbVie as it reflects the company's commitment to incentivizing its leadership through stock ownership. It also sets a precedent for other pharmaceutical companies regarding director compensation practices.
What's Next
The filing does not say what happens next.
Details of the Transaction
The transaction involved the acquisition of 129 stock equivalent units, with a total transaction value of $33,807.11, calculated at the price of $261.59 per unit. This acquisition was executed under the transaction code 'A', indicating it was an acquisition of securities.
Ownership Structure
Post-transaction, Edward J. Rapp holds a total of 29,568 shares, which includes the newly acquired stock equivalent units. The filing specifies that Rapp's ownership is direct, reflecting a straightforward relationship with the securities.
Compensation Structure
According to the filing, the stock equivalent units are credited to a specific account under the director's grantor trust. These units earn returns equivalent to those of AbbVie stock, aligning the director's financial interests with the company's performance. The distribution of these units occurs over a period that corresponds to the director's years of service, commencing at either age 65 or upon retirement from the board.
Additional Context
The filing does not provide information on any prior transactions by Rapp or other directors, nor does it detail the overall compensation strategy of AbbVie beyond this specific transaction.